Literature DB >> 11001606

Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients.

S R McGurk1, P J Moriarty, P D Harvey, M Parrella, L White, J Friedman, K L Davis.   

Abstract

The authors assessed whether cognitive functioning and negative symptoms are related to functional outcome across severity of negative symptoms and examined relationships between symptom domains in patients with high versus low negative symptom severity. The interrelationships between cognitive functioning and functional skills in poor-outcome geriatric schizophrenic patients were compared between those who were in the first (n = 81) and the fourth quartiles (n = 127) of negative symptom severity based on the normative data in the Positive and Negative Syndrome Scale. It was found that negative symptoms and cognitive functioning were the strongest correlates of functional status in geriatric poor-outcome schizophrenic patients--regardless of negative symptom severity. Interestingly, the greater the severity of negative symptoms, the less strongly negative symptoms were related to functional outcome. The present findings demonstrate that the relationship of cognitive functioning to social and adaptive functioning remains significant despite differing levels of negative symptom severity.

Entities:  

Mesh:

Year:  2000        PMID: 11001606     DOI: 10.1176/jnp.12.2.257

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  15 in total

Review 1.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

2.  Predictors of quality of life in schizophrenia.

Authors:  Jean Caron; Yves Lecomte; Emmanuel Stip; Suzanne Renaud
Journal:  Community Ment Health J       Date:  2005-08

3.  Characterizing and explaining differences in cognitive test performance between african american and European American older adults.

Authors:  Adrienne Aiken Morgan; Michael Marsiske; Keith E Whitfield
Journal:  Exp Aging Res       Date:  2008 Jan-Mar       Impact factor: 1.645

Review 4.  Impairment in functional capacity as an endophenotype candidate in severe mental illness.

Authors:  Philip D Harvey; Margaret M McClure; Thomas L Patterson; John A McGrath; Ann E Pulver; Christopher R Bowie; Larry J Siever
Journal:  Schizophr Bull       Date:  2011-05-11       Impact factor: 9.306

5.  Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.

Authors:  Buranee Kanchanatawan; Solaphat Hemrungrojn; Supaksorn Thika; Sunee Sirivichayakul; Kiat Ruxrungtham; André F Carvalho; Michel Geffard; George Anderson; Michael Maes
Journal:  Mol Neurobiol       Date:  2017-09-05       Impact factor: 5.590

Review 6.  Management of schizophrenia in late life with antipsychotic medications: a qualitative review.

Authors:  Takefumi Suzuki; Gary Remington; Hiroyuki Uchida; Tarek K Rajji; Ariel Graff-Guerrero; David C Mamo
Journal:  Drugs Aging       Date:  2011-12-01       Impact factor: 3.923

Review 7.  Cognition in schizophrenia.

Authors:  P D Harvey; C R Bowie; J I Friedman
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 8.  Management of negative symptoms of schizophrenia.

Authors:  D C Javitt
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

9.  Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies.

Authors:  V S Gabrovska-Johnson; M Scott; S Jeffries; N Thacker; R C Baldwin; A Burns; S W Lewis; J F W Deakin
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.

Authors:  Fernando Cañas; Víctor Pérez-Solá; Silvia Díaz; Javier Rejas
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.